Editas Medicine: HC Wainwright Raises PT to $5 from $4 on Buy Rating

Editas Medicine: HC Wainwright Raises PT to $5 from $4 on Buy Rating

HC Wainwright & Co. has raised its price target for Editas Medicine (EDIT) to $5.00 from $4.00, maintaining a "Buy" rating on the stock [1]. This adjustment marks a 25% increase in the target price, reflecting a more optimistic outlook on the stock's potential performance.

Editas Medicine is a clinical-stage genome editing company focused on developing transformative genomic medicines to treat a broad range of serious diseases. The company's proprietary gene editing platform is based on CRISPR technology, which uses a protein-RNA complex to recognize and edit specific DNA sequences [2].

The latest earnings report from Editas Medicine indicated a loss of $0.63 per share, missing analysts' estimates, but exceeding revenue expectations with $3.58 million reported [3]. Despite the earnings miss, the company's strong cash position and operational runway into the second quarter of 2027 suggest that it is well-positioned for future growth [4].

The consensus recommendation from brokerage firms is currently "Hold," with an average 12-month price target of $5.10 [3]. However, the recent price target increase by HC Wainwright indicates a shift in sentiment among analysts.

Editas Medicine's lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD) and transfusion-dependent beta-thalassemia [2]. The company is also developing EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis.

The stock has shown volatility in recent months, trading between $0.91 and $4.12 over the past year. Institutional investors own 71.90% of the company's stock [3].

References:
[1] https://www.gurufocus.com/news/3092849/editas-medicine-edit-sees-analyst-price-target-raised-by-wells-fargo-edit-stock-news
[2] https://www.marketscreener.com/news/editas-medicine-picks-edit-401-gene-editing-drug-as-lead-in-vivo-development-candidate-ce7c50d3de8bf123
[3] https://www.marketbeat.com/instant-alerts/editas-medicine-inc-nasdaqedit-receives-consensus-recommendation-of-hold-from-analysts-2025-08-31/
[4] https://www.morningstar.com/news/globe-newswire/9521261/editas-medicine-nominates-edit-401-an-ldlr-targeted-medicine-as-lead-in-vivo-development-candidate